Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024)

Artiva Biotherapeutics (ARTV) reported EBITDA Margin of 5603.19% for Q1 2024, down 734.32% quarter-over-quarter from 671.59% in Q4 2023.

Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of EBITDA Margin data on file, last reported at 5603.19% in Q1 2024.

EBITDA Margin for Q1 2024 came in at 5603.19%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was 26219.12% (changed N/A YoY), and the FY2024 annual result was 26219.12%, down 2613283.0% from the prior year.
EBITDA Margin declined to 5603.19% in Q1 2024 per ARTV's latest filing, from 671.59% in the prior quarter.
Over five years, EBITDA Margin peaked at 42.85% in Q3 2023 and troughed at 5603.19% in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-6.43%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	38.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Artiva Biotherapeutics	241.85 Mn	241.85 Mn	-	-

Download Data